STOCKHOLM, Feb. 28, 2025 /PRNewswire/ -- In connection with the publication of results from two independent research studies on ColdZyme, Enzymatica AB invites to a digital press briefing on 5 March 2025.

13:00-14:10 The researchers will present their findings and be available for questions
14:15-15:00 Enzymatica's CEO, Claus Egstrand, and Chairman, Bengt Baron, will present a company overview and be available for questions

The press briefing will be broadcast live. To participate in the live discussion, please register via this link: https://creo-live.creomediamanager.com/eda7c0f6-7107-4d87-b409-82bdf2d58605

Read the press release published on 28 February here:
https://www.enzymatica.com/media/press-releases/2025/new-independent-studies-show-that-coldzyme-addresses-the-root-cause-of-respiratory-infections-reducing-sick-days-and-symptoms/

Link to the published article in The Journal of Physiology:
https://physoc.onlinelibrary.wiley.com/doi/10.1113/JP288136

CONTACT:

For more information, contact:
Anja Tragardh, Corporate Communications, Enzymatica AB
Email: anja.tragardh@enzymatica.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/enzymatica-ab/r/invitation-to-press-briefing---5-march-2025,c4112958

The following files are available for download:


     
     https://mb.cision.com/Main/18091/4112958/3293766.pdf Press
                                                              invitation_Enzymatica_5March2025_eng

View original content:https://www.prnewswire.co.uk/news-releases/enzymatica-ab--invitation-to-press-briefing--5-march-2025-302388816.html

Tags

More Like This

Enzymatica AB - Interim report Q3/2023: Research results that reshape the competitive landscape

Enzymatica AB's Interim report Q3/2024: Focus on developing existing and new markets

Enzymatica AB Year-end report 2024: Strong performance in core markets - preparing for international growth

Interim report Q2/2024: Enzymatica builds momentum for expansion

Enzymatica's Board of Directors decides on a new rights issue of approximately SEK 130 million

Enzymatica's Board of Directors decides on a new rights issue of SEK 27.4 million

Enzymatica's Board of Directors updates the financial targets

Year-end report 2023: Scientific and regulatory progress generating international interest